4DMedical presents at BP Healthcare Conference

This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as at 9 November 2021 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information

onlyand does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (Corporations Act) or other

useoffer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

Financial data

ersonalA dollar values are in Australian dollars ($ or A$) unless otherwise stated. Any financial data in this presentation is unaudited.

P st performance

The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

2

Future performance

This presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "could", "would", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward-looking statements in this presentation include statements regarding the Company's future growth options, strategies and new products. Forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward-looking statements in this presentation speak only as of the date of this presentation.

Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.

use

• Approximately 377 million respiratory diagnostics tests performed per annum globally
• Existing lung diagnostics are decades out of date, not fit for purpose and ripe for displacement
• Initial focus on the U.S. respiratory diagnostic market worth US$13.7 billion per annum

ersonal3

• Offering is focused on improving hospital and patient outcomes with limited capex requirements
• Capital light business model with rapid SaaS deployment - expected >90% gross margin
• Significant barriers to entry: first mover, strong IP portfolio and advanced product pipeline
• Strong balance sheet, with A$72.2m cash in bank as at 30 September 2021

~US$31 billion global lung diagnostics market opportunity ripe for disruption

Global lung diagnostics market

• Initial focus is on penetrating the U.S. and onlyAustralian markets representing a US$13.7bn and US$285m opportunity respectively

• Given the large market size, even low market

date having made insignificant advancements over the last 50 years

• Approximately 99% of all lung diagnostics are

sensitivity, cost and radiation exposure, while failing to provide a comprehensive insight into the form and function of the patient's lungs

5 Frost & Sullivan 2020 (per annum)

Computed

Tomography (CT)

Procedures

44.5m

Expenditure

Nuclear US$11.9bn

Medicine

Procedures

1.4m

Expenditure

US$1.6bn

Pulmonary

Function Tests

Procedures

78.9m

Expenditure

US$3.4bn

X-ray Technology

Procedures

253.0m

Expenditure

US$14.5bn